Oncolytics Biotech Inc.
$1.11
▲
3.25%
2026-04-21 08:38:01
oncolyticsbiotech.com
NCM: ONCY
Explore Oncolytics Biotech Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$163.05 M
Current Price
$1.11
52W High / Low
$1.85 / $0.45
Stock P/E
—
Book Value
$0
Dividend Yield
—
ROCE
-1939.57%
ROE
11480.64%
Face Value
—
EPS
$-0.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
0.99
Debt / Equity
-0.15
Current Ratio
1.12
Quick Ratio
1.12
Forward P/E
-3.93
Price / Sales
—
Enterprise Value
$103.36 M
EV / EBITDA
-3.61
EV / Revenue
—
Rating
Buy
Target Price
$5.27
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
| 2. | Savara Inc. | $5.61 | — | $1.15 B | — | -52.68% | -63.45% | $7 / $1.89 | $0.8 |
| 3. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
| 4. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 5. | Beam Therapeutics Inc. | $31.19 | — | $3.2 B | — | -27.72% | -8.11% | $36.44 / $15.35 | $12.48 |
| 6. | aTyr Pharma, Inc. | $0.85 | — | $83.68 M | — | -99.71% | -1.08% | $7.29 / $0.64 | $0.69 |
| 7. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.65 M | -9.94 M | -4.17 M | -4.89 M | -4.73 M | — |
| Net Profit | -9.18 M | -10.35 M | -4.51 M | -4.67 M | -4.56 M | — |
| EPS in Rs | -0.08 | -0.09 | -0.04 | -0.04 | -0.04 | -0.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -28.73 M | -25.54 M | -25.47 M | -19.84 M |
| Net Profit | -28.76 M | -22.79 M | -20.92 M | -18.3 M |
| EPS in Rs | -0.25 | -0.2 | -0.18 | -0.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.58 M | 13.42 M | 29.26 M | 27.51 M |
| Total Liabilities | 11.38 M | 10.12 M | 8.49 M | 7.98 M |
| Equity | -3.8 M | 3.3 M | 20.78 M | 19.53 M |
| Current Assets | 6.84 M | 12.44 M | 28.78 M | 26.29 M |
| Current Liabilities | 6.1 M | 4.88 M | 3.19 M | 2.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -20.11 M | -19.88 M | -21.44 M | -17.21 M |
| Investing CF | -0.01 M | -0.17 M | 15.24 M | -15.03 M |
| Financing CF | 14.12 M | 5.03 M | 24.12 M | 8.99 M |
| Free CF | -20.12 M | -20.06 M | -21.45 M | -17.25 M |
| Capex | -0.01 M | -0.17 M | -0.01 M | -0.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -8.96% | -14.32% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.